<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34882653</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1545-861X</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>49</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>10</Day></PubDate></JournalIssue><Title>MMWR. Morbidity and mortality weekly report</Title><ISOAbbreviation>MMWR Morb Mortal Wkly Rep</ISOAbbreviation></Journal><ArticleTitle>Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2020-June 2021.</ArticleTitle><Pagination><StartPage>1691</StartPage><EndPage>1699</EndPage><MedlinePgn>1691-1699</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15585/mmwr.mm7049a1</ELocationID><Abstract><AbstractText>As of May 1, 2016, use of oral poliovirus vaccine (OPV) type 2 for routine and supplementary immunization activities ceased after a synchronized global switch from trivalent OPV (tOPV; containing Sabin strain types 1, 2, and 3) to bivalent OPV (bOPV; containing Sabin strain types 1 and 3) subsequent to the certified eradication of wild type poliovirus (WPV) type 2 in 2015 (1-3). Circulating vaccine-derived poliovirus (cVDPV) outbreaks* occur when transmission of Sabin strain poliovirus is prolonged in underimmunized populations, allowing viral genetic reversion to neurovirulence, resulting in cases of paralytic polio (1-3). Since the switch, monovalent OPV type 2 (mOPV2, containing Sabin strain type 2) has been used for response to cVDPV type 2 (cVDPV2) outbreaks; tOPV is used if cVDPV2 co-circulates with WPV type 1, and bOPV is used for cVDPV type 1 (cVDPV1) or type 3 (cVDPV3) outbreaks (1-4). In November 2020, the World Health Organization (WHO) Emergency Use Listing procedure authorized limited use of type 2 novel OPV (nOPV2), a vaccine modified to be more genetically stable than the Sabin strain, for cVDPV2 outbreak response (3,5). In October 2021, the Strategic Advisory Group of Experts on Immunization (WHO's principal advisory group) permitted wider use of nOPV2; however, current nOPV2 supply is limited (6). This report updates that of July 2019-February 2020 to describe global cVDPV outbreaks during January 2020-June 2021 (as of November 9, 2021)<sup>†</sup> (3). During this period, there were 44 cVDPV outbreaks of the three serotypes affecting 37 countries. The number of cVDPV2 cases increased from 366 in 2019 to 1,078 in 2020 (7). A goal of the Global Polio Eradication Initiative's (GPEI) 2022-2026 Strategic Plan is to better address the challenges to early CVDPV2 outbreak detection and initiate prompt and high coverage outbreak responses with available type 2 OPV to interrupt transmission by the end of 2023 (8).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alleman</LastName><ForeName>Mary M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Jorba</LastName><ForeName>Jaume</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Diop</LastName><ForeName>Ousmane M</ForeName><Initials>OM</Initials></Author><Author ValidYN="Y"><LastName>Shaukat</LastName><ForeName>Shahzad</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Traoré</LastName><ForeName>Mohamed A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Wiesen</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Wassilak</LastName><ForeName>Steven G F</ForeName><Initials>SGF</Initials></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Cara C</ForeName><Initials>CC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>MMWR Morb Mortal Wkly Rep</MedlineTA><NlmUniqueID>7802429</NlmUniqueID><ISSNLinking>0149-2195</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012703" MajorTopicYN="N">Serotyping</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>9</Day><Hour>17</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34882653</ArticleId><ArticleId IdType="pmc">PMC8659190</ArticleId><ArticleId IdType="doi">10.15585/mmwr.mm7049a1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jorba J, Diop OM, Iber J, et al. Update on vaccine-derived poliovirus outbreaks—worldwide, January 2018–June 2019. MMWR Morb Mortal Wkly Rep 2019;68:1024–8. 10.15585/mmwr.mm6845a4</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6845a4</ArticleId><ArticleId IdType="pmc">PMC6855511</ArticleId><ArticleId IdType="pubmed">31725706</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. Standard operating procedures. Responding to a poliovirus event or outbreak. Geneva, Switzerland: World Health Organization; 2020. https://polioeradication.org/wp-content/uploads/2020/04/POL-SOP-V3.1-20200424.pdf</Citation></Reference><Reference><Citation>Alleman MM, Jorba J, Greene SA, et al. Update on vaccine-derived poliovirus outbreaks—worldwide, July 2019–February 2020. MMWR Morb Mortal Wkly Rep 2020;69:489–95. 10.15585/mmwr.mm6916a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6916a1</ArticleId><ArticleId IdType="pmc">PMC7188410</ArticleId><ArticleId IdType="pubmed">32324719</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffett DB, Llewellyn A, Singh H, et al. Progress toward poliovirus containment implementation—worldwide, 2019–2020. MMWR Morb Mortal Wkly Rep 2020;69:1330–3. 10.15585/mmwr.mm6937a7</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6937a7</ArticleId><ArticleId IdType="pmc">PMC7498175</ArticleId><ArticleId IdType="pubmed">32941411</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Polio vaccine—novel oral (nOPV) monovalent type 2. Geneva, Switzerland: World Health Organization; 2020. https://extranet.who.int/pqweb/vaccines/polio-vaccine-novel-oral-nopv-monovalent-type-2</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. Independent experts advise move to next use phase for novel oral polio vaccine type 2. Geneva, Switzerland: World Health Organization; 2021. https://polioeradication.org/news-post/independent-experts-advise-transition-to-next-use-phase-for-novel-oral-polio-vaccine-type-2-nopv2/</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. Circulating vaccine-derived poliovirus. Global circulating vaccine-derived poliovirus (cVDPV) as of 30 November 2021; Geneva, Switzerland: World Health Organization. Accessed November 30, 2021. https://polioeradication.org/polio-today/polio-now/this-week/circulating-vaccine-derived-poliovirus/</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. Polio eradication strategy 2022–2026: delivering on a promise. Geneva, Switzerland: World Health Organization; 2021. https://polioeradication.org/gpei-strategy-2022-2026/</Citation></Reference><Reference><Citation>World Health Organization.
Statement of the twenty-ninth Polio IHR Emergency Committee. Geneva, Switzerland: World Health Organization; 2021. https://www.who.int/news/item/20-08-2021-statement-of-the-twenty-ninth-polio-ihr-emergency-committee</Citation></Reference><Reference><Citation>Zomahoun DJ, Burman AL, Snider CJ, et al. Impact of COVID-19 pandemic on global poliovirus surveillance. MMWR Morb Mortal Wkly Rep 2021;69:1648–52. 10.15585/mmwr.mm695152a4</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm695152a4</ArticleId><ArticleId IdType="pmc">PMC9191906</ArticleId><ArticleId IdType="pubmed">33382673</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>